December 16, 2015
AstraZeneca divests Entocort US rights to Perrigo for $380M
AstraZeneca has completed its agreement with Perrigo Company plc for the divestment of US rights to Entocort.
Pharmaceuticals, Biotechnology and Life Sciences
AstraZeneca has completed its agreement with Perrigo Company plc for the divestment of US rights to Entocort.